An Acceptable Incidence of Infusion Site Reactions after Subcutaneous Bortezomib Administration in the Upper Arm in Japanese Patients with Multiple Myeloma

被引：1
|
作者：
Ohgiya, Daisuke [1 ]
Tsuchiya, Takahide [1 ]
Suyama, Takahiro [1 ]
Watanabe, Shigeki [1 ]
Numata, Hiroki [2 ]
Tsuboi, Kosuke [2 ]
Sasao, Tamotsu [2 ]
机构：
[1] Ebina Gen Hosp, Dept Hematol, Ebina, Kanagawa 2430433, Japan
[2] Ozawa Hosp, Dept Hematol, Odawara, Kanagawa, Japan
来源：
ACTA HAEMATOLOGICA | 2015年 / 133卷 / 01期
关键词：
D O I：
10.1159/000362587
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：29 / 30
页数：2
相关论文
共 44 条
  • [21] Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: Incidence, mortality and clinical characterization
    Yoshizawa, Kazutake
    Mukai, Harumi Y.
    Miyazawa, Michiko
    Miyao, Makiko
    Ogawa, Yoshimasa
    Ohyashiki, Kazuma
    Katoh, Takao
    Kusumoto, Masahiko
    Gemma, Akihiko
    Sakai, Fumikazu
    Sugiyama, Yukihiko
    Hatake, Kiyohiko
    Fukuda, Yuh
    Kudoh, Shoji
    CANCER SCIENCE, 2014, 105 (02): : 195 - 201
  • [22] Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma
    Xu, Yan
    Deng, Shuhui
    Mao, Xuehan
    An, Gang
    Li, Zengjun
    Wang, Yafei
    Fulciniti, Mariateresa
    Ho, Matthew
    Lin, Jianhong
    Sui, Weiwei
    Liu, Wei
    Zou, Dehui
    Yi, Shuhua
    Huang, Wenyang
    Liu, Hong
    Lv, Rui
    Li, Jian
    Wang, Tingyu
    Du, Chenxing
    Munshi, Nikhil C.
    Qiu, Lugui
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (06): : 422 - 430
  • [23] Home is best. Self-administration of subcutaneous Bortezomib at home in patients with multiple myeloma-A mixed method study
    Kirkegaard, Jannie
    Lundholm, Birgitte Wolf
    Rosenberg, Tine
    Lund, Thomas
    Gundesen, Michael Tveden
    Dieperink, Karin Brochstedt
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2022, 60
  • [24] Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
    Moreau, Philippe
    Pylypenko, Halyna
    Grosicki, Sebastian
    Karamanesht, Ievgenii
    Leleu, Xavier
    Grishunina, Maria
    Rekhtman, Grigoriy
    Masliak, Zvenyslava
    Robak, Tadeusz
    Shubina, Anna
    Arnulf, Bertrand
    Kropff, Martin
    Cavet, James
    Esseltine, Dixie-Lee
    Feng, Huaibao
    Girgis, Suzette
    van de Velde, Helgi
    Deraedt, William
    Harousseau, Jean-Luc
    LANCET ONCOLOGY, 2011, 12 (05): : 431 - 440
  • [25] Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
    Kenta Yamaoka
    Kei Irie
    Nobuhiro Hiramoto
    Masaki Hirabatake
    Hiroaki Ikesue
    Tohru Hashida
    Tadashi Shimizu
    Takayuki Ishikawa
    Nobuyuki Muroi
    Investigational New Drugs, 2023, 41 : 761 - 767
  • [26] Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
    Yamaoka, Kenta
    Irie, Kei
    Hiramoto, Nobuhiro
    Hirabatake, Masaki
    Ikesue, Hiroaki
    Hashida, Tohru
    Shimizu, Tadashi
    Ishikawa, Takayuki
    Muroi, Nobuyuki
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (05) : 761 - 767
  • [27] Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy
    Minarik, Jiri
    Pavlicek, Petr
    Pour, Ludek
    Pika, Tomas
    Maisnar, Vladimir
    Spicka, Ivan
    Jarkovsky, Jiri
    Krejci, Marta
    Bacovsky, Jaroslav
    Radocha, Jakub
    Straub, Jan
    Kessler, Petr
    Wrobel, Marek
    Walterova, Lenka
    Sykora, Michal
    Obernauerova, Jarmila
    Brozova, Lucie
    Gregora, Evzen
    Adamova, Dagmar
    Gumulec, Jaromir
    Adam, Zdenek
    Scudla, Vlastimil
    Hajek, Roman
    PLOS ONE, 2015, 10 (04):
  • [28] Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group
    Minarik, Jiri
    Pavlicek, Petr
    Pour, Ludek
    Pika, Tomas
    Maisnar, Vladimir
    Spicka, Ivan
    Jarkovsky, Jiri
    Krejci, Marta
    Bacovsky, Jaroslav
    Radocha, Jakub
    Straub, Jan
    Kessler, Petr
    Wrobel, Marek
    Walterova, Lenka
    Sykora, Michal
    Obernauerova, Jarmila
    Gregora, Evzen
    Adamova, Dagmar
    Gumulec, Jaromir
    Adam, Zdenek
    Scudla, Vlastimil
    Hajek, Roman
    BLOOD, 2014, 124 (21)
  • [29] INITIATION OF SUBCUTANEOUS BORTEZOMIB IN AN OUTPATIENT CLINIC SETTING: A NURSE-LED PROJECT TO REDUCE THE INCIDENCE OF PERIPHERAL NEUROPATHY IN MULTIPLE MYELOMA PATIENTS.
    Eckenfels, Michael
    Prokopiou, Carmelita
    Horowitz, Sandra
    Jacobs, RaShaundra
    Orlowski, Robert
    Duplechan, Margaret
    Abbasi, Toni
    ONCOLOGY NURSING FORUM, 2012, 39 (03) : E167 - E167
  • [30] A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma
    Moreau, Philippe
    Pylypenko, Halyna V.
    Grosicki, Sebastian
    Karamanesht, Evgeniy E.
    Leleu, Xavier
    Grishunina, Maria E.
    Rekhtman, Grigoriy B.
    Masliak, Zvenyslava
    Robak, Tadeusz
    Shubina, Anna V.
    Fermand, Jean-Paul
    Kropff, Martin
    Cavet, James
    Parasuraman, Sudha
    Feng, Huaibao
    Skee, Donna M.
    van de Velde, Helgi
    Deraedt, William M.
    Harousseau, Jean-Luc
    BLOOD, 2010, 116 (21) : 142 - 142
12345